Blue Planet Prize 2025: Announcement of Prize Laureates
TOKYO--(BUSINESS WIRE)--This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates.
1. Professor Robert B. Jackson (USA) Born on September 26, 1961
Department of Earth System Science, Stanford University
Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions.
2. Dr. Jeremy Leggett (UK) Born on March 16, 1954
Founder and CEO of Highlands Rewilding Ltd.
Inaugural chairman of the Carbon Tracker Initiative
Dr. Jeremy Leggett, as the inaugural chairman of the Carbon Tracker Initiative (CTI), introduced the concept of the "carbon bubble," highlighting the economic risks associated with fossil fuel assets. Through CTI's activities, he influenced investors and policymakers, advancing the divestment movement. In addition, as a practical effort to balance economic activity with environmental conservation, he founded one of the UK's leading solar energy companies. More recently, he has been spearheading initiatives in Scotland to connect ecological restoration with community prosperity.
Each laureate is presented with a certificate of merit, a commemorative trophy, and 500,000 US dollars in prize money.
The Award Ceremony is scheduled on Wednesday, October 29, 2025, at Tokyo Kaikan. Commemorative lectures will be given on October 30th and November 1st, 2025, at the University of Tokyo and at the Kyoto International Community House (kokoka), respectively.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples
Large-scale study aims to create comprehensive map of the human proteome to monitor changes reflecting human health and disease UPPSALA, Sweden, June 12, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale proteomics investigation involving nearly 200,000 patient samples from the Geisinger Health Study that aims to unlock new insights into the dynamic biology and mechanisms of human disease. The Geisinger Health Study, characterized by deep phenotyping data, offers a unique opportunity to monitor proteomic changes at scale. RGC's established infrastructure is designed to manage large-scale projects and is built for the efficient execution of this ambitious endeavor. RGC's selection of Olink Explore HT follows the platform's selection for use in the UK Biobank Pharma Proteomics Project (UKB-PPP), the world's largest human proteomics study. The Geisinger Health Study aims to validate genetic hypotheses, solidify drug targets identified by RGC's world-class genomic sequencing operation, and discover novel disease biomarkers to improve drug development efficiencies. Olink Explore HT was chosen for its unparalleled scalability, high throughput, and superior specificity, all of which are essential for processing such a vast number of samples. "We are thrilled to partner with RGC on this groundbreaking project," said Carl Raimond, president, proteomic sciences, Thermo Fisher Scientific. "The selection of Olink Explore HT underscores its ability to deliver robust and reliable data at scale. This important work will accelerate the pace of biomarker discovery and contribute significantly to the advancement of precision medicine." RGC is a cutting-edge research organization focused on uncovering genetic and proteomic insights, ensuring superb data stewardship, and ultimately driving scientific advancements in preventing and treating human disease. The integration of Olink Explore HT into their workflow signifies another major step forward in their commitment to leveraging multi-omics data for improved outcomes. "The Olink Explore HT platform has proven to be an invaluable tool in our pursuit of deeper biological understanding," stated John Overton, Vice President at Regeneron Genetics Center. "Its scalability and specificity are essential for handling the complexities of a project of this size. We believe this ambitious endeavor will yield transformative insights that will drive innovation in scientific discoveries." The comprehensive mapping of protein levels across such a large population of patient samples represents a significant milestone in the field of proteomics, paving the way for future studies to advance our understanding of human health and disease. Learn more about Olink Explore HT. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact: Michael B. Gonzales, PhDThermo Fisher ScientificE-mail: Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
- GLIMPSE-1 model achieves state-of-the-art performance in antibody humanization and optimization, enabling scalable, structure-free biologic design from native human immune sequences ALAMEDA, Calif., June 12, 2025--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. "Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years," said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. "With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines." GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: Best-in-class performance in antibody humanization benchmarks compared to nine leading antibody language models Successful affinity optimization across multiple targets, producing sub-nanomolar variants while addressing developability concerns Creation of highly divergent functional antibody variants with <90% sequence identity to parent sequences Species cross-reactivity engineering across human, cynomolgus monkey, and murine targets Engineering for formulation-preferred parameters such as isoelectric point while maintaining binding affinity GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune. View source version on Contacts Media Kimberly HaKKH
Associated Press
31 minutes ago
- Associated Press
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 12, 2025-- Infinimmune, a biotechnology company pioneering human-first antibody discovery and design, today announced the launch of GLIMPSE-1, a protein language model trained solely on native human antibody sequences. Developed using millions of paired heavy and light chains from human memory B cells, GLIMPSE-1 represents a new paradigm for therapeutic antibody engineering that applies the design principles of the human adaptive immune system. Infinimmune published results in a new bioRxiv preprint, demonstrating that GLIMPSE-1 can humanize clinical antibodies, engineer for affinity and developability parameters, and generate highly divergent functional variants, all through in silico design guided by the biology of the human adaptive immune system. 'Fully human antibodies carry the evolutionary fingerprints of the human immune system, optimized over millions of years,' said Wyatt McDonnell, Ph.D., Co-Founder and CEO, Infinimmune. 'With GLIMPSE-1, we can decode and encode that logic directly from immune repertoires to discover and design better, safer biologics from day one. This approach complements the FDA's recent focus on assessing human-relevant methods for therapeutic development, which could ultimately benefit patients through more comprehensive safety assessment. We believe models like GLIMPSE-1 will remain essential in the discovery and development of modern antibody medicines.' GLIMPSE-1 was developed as a core component of Infinimmune's therapeutic development capabilities, strengthening the company's pipeline of antibody drug candidates. The model was trained using a large, diverse dataset with proprietary sequences from Infinimmune's Complete Human® and Anthrobody® technologies, which source antibodies directly from native human repertoires, allowing it to learn the biological and functional constraints of human immunity. Key results from the preprint include: GLIMPSE-1 operates entirely in human antibody sequence space, predicting viable antibody variants without 3D structure modeling, energy calculations, or experimental screening beforehand. The resulting antibodies maintain essential functional properties and characteristics consistent with clinically approved monoclonal antibodies, all guided by patterns learned from human immune systems. The development of GLIMPSE-1 aligns with recent FDA initiatives exploring human-relevant methodologies for therapeutic development. The FDA's roadmap for integrating New Approach Methodologies (NAMs) identifies monoclonal antibodies as an initial focus area, creating an environment where human-first models like GLIMPSE-1 may provide valuable complementary insights. Infinimmune has successfully integrated GLIMPSE-1 into its therapeutic antibody development pipeline, where the model has significantly contributed to the engineering and optimization of the company's lead programs. The company is currently exploring strategic partnerships with pharmaceutical and biotechnology companies to apply GLIMPSE-1's capabilities to partner's therapeutic programs. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit and follow us on LinkedIn and @infinimmune. View source version on CONTACT: Media Kimberly Ha KKH Advisors 917-291-5744 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: RESEARCH TECHNOLOGY GENETICS SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ARTIFICIAL INTELLIGENCE OTHER SCIENCE SOURCE: Infinimmune Copyright Business Wire 2025. PUB: 06/12/2025 08:07 AM/DISC: 06/12/2025 08:05 AM
